Tomohiro Sakamoto
Tottori University Hospital · 72 works · 1,653 citations · h-index 15
Top works
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
- 1320MO Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088
- PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers
- First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations
- Multiplex gene‐panel testing for lung cancer patients
- Phase II study of tepotinib in NSCLC patients with METex14 mutations.
- Nivolumab‑induced cholangitis in patients with non‑small cell lung cancer: Case series and a review of literature
- Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer
- Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer
- Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations
- Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations
- Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer
- Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study
- Pembrolizumab‑induced aseptic meningitis in a patient with non‑small cell lung cancer: A case report and literature review of aseptic meningitis as an immune‑related adverse event
- Successful Switch to Afatinib and Osimertinib Rechallenge with Corticosteroids after Osimertinib-induced Interstitial Lung Disease: A Case Report and Literature Review
- P49-6 Two cases of unexpected cardiac tamponade as pseudoprogression due to immune checkpoint inhibitor in patients with advanced lung adenocarcinoma
- Frequency of Epidermal Growth Factor Receptor Mutation in Smokers with Lung Cancer Without Pulmonary Emphysema
- Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non–Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L)
- A Single-Arm Phase 2 Study of Sotorasib Plus Carboplatin and Pemetrexed in Patients With Advanced Nonsquamous NSCLC With KRAS G12C Mutation (WJOG14821L, SCARLET)
- Long‐term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study